Clinical Trial Details
| Trial ID: | L3763 |
| Source ID: | NCT02284269 |
| Associated Drug: | Sglt2 Inhibitors |
| Title: | Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: SGLT2 Inhibitors |
| Outcome Measures: | Primary: Incidence of adverse events, up to 3 years | Secondary: Incidence of cardiovascular events, up to 3 years|Incidence of cancer, up to 3 years|The change from baseline in vital signs and laboratory data, Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration|Incidence of other adverse events, up to 3 years|Incidence of drug-related adverse events, up to 3 years|Incidence of serious adverse events, up to 3 years|The change from baseline in HbA1c, Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration|The change from baseline in Fasting Plasma Glucose, Baseline and 3 months, 6 months, 1 year, 2 years, 3 years after administration |
| Sponsor/Collaborators: | Sponsor: Pharmaceuticals and Medical Devices Agency, Japan |
| Gender: | ALL |
| Age: | CHILD, ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 18000 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2014-10 |
| Completion Date: | |
| Results First Posted: | |
| Last Update Posted: | 2016-04-04 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT02284269 |
